Mati Therapeutics Inc., a biotechnology firm based in Austin, TX, has successfully completed a $2.2 million equity fundraising round as reported in their recent SEC Form D filing. The offering, which took place on September 12, 2025, was fully subscribed by a single investor.
Related articles
Press ReleaseJune 19, 2026
Discovery 2026 Short Duration LP Initial Public Offering – Maximum $35,000,000
June 19, 2026
Press ReleaseJune 19, 2026
FULL CIRCLE LITHIUM ANNOUNCES $5.0 MILLION NON-BROKERED PRIVATE PLACEMENT
June 19, 2026
Press ReleaseJune 19, 2026
LUMIQ Raises Strategic Funding to Become the AI Decision Layer for Financial Services
June 19, 2026
← Back to all articles
Generated by Olivia 6